SSA
PSTV

Schonfeld Strategic Advisors’s Plus Therapeutics PSTV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-508
Closed -$60.4K – 2534
2022
Q4 		$60.4K Buy
+508
New +$80.9K ﹤0.01% 2247

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GVAG
Great Valley Advisor Group Wilmington, Delaware $5.5B AUM 20.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Schonfeld Strategic Advisors's PSTV Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Plus Therapeutics (PSTV) in Q1 2023, closing a stake of 508 shares — an estimated $60.4K sold.

Schonfeld Strategic Advisors first reported a position in PSTV in Q4 2022 and held it in 1 quarter. The position peaked at $60.4K in Q4 2022. 16 funds tracked by Wall St. Rank hold PSTV as of Q1 2023.

  • Schonfeld Strategic Advisors reported no remaining Plus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 508 Plus Therapeutics shares in Q1 2023, an estimated $60.4K.
  • Schonfeld Strategic Advisors first reported a position in Plus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Plus Therapeutics position peaked at $60.4K in Q4 2022.
  • 16 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.